

Special Issue

Developments in Microangiopathic Hemolytic Anemia Disease Presentations

Message from the Guest Editor

Thrombotic thrombocytopenic purpura is a severe disease that can lead to significant morbidity and potentially mortality due to the diffuse formation of microthrombi affecting all organ systems. For over three decades, therapeutic plasma exchange (TPE), an apheresis procedure that exchanges the patient's plasma with donated plasma, has been the first-line therapy for this disease. Reports outlining the benefits of using the monoclonal rituximab in the setting of TTP continue to grow in the literature. Furthermore, the recent approval and use of the monoclonal antibody caplacizumab, the first TTP-specific therapy that prevents the binding of vWF to platelets, have improved the chances of earlier platelet recovery and result in shorter hospitalizations.

Thus, the goal of this Special Issue is to invite submissions that outline advances in our understanding of TTP. We welcome novel research from basic science to translational and clinical work in TTP as well as comprehensive reviews of available data of the latest discoveries. Submissions of case reports, unless they are in the context of a comprehensive review of the relevant literature, are not encouraged.

Guest Editor

Dr. Robert Maitta

Department of Pathology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA

Deadline for manuscript submissions

closed (31 May 2025)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/203250

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).